Generate Biomedicines, Inc. (GENB) — IPO Analysis
By Kian O Connor | Updated 4/29/2026
Company Overview
Performance Overview
Since going public at $12.45 per share on Feb 27, 2026, Generate Biomedicines, Inc. shares have gained 0.2%, rewarding investors who participated in the IPO. The stock currently trades at $12.47, giving the company a market capitalization of $1.6B.
Lockup Expiration
The lockup period for Generate Biomedicines, Inc. insiders is set to expire on Aug 26, 2026, which is 119 days from now. When the lockup expires, insiders and early investors who received shares before the IPO will be free to sell their holdings on the open market. This can create significant selling pressure and is closely watched by traders and institutional investors alike.
Industry Context
Generate Biomedicines, Inc. operates in the Pharmaceutical Preparations sector, which has seen varied IPO activity in recent years. The company is headquartered in MA and is classified under SIC code 2834. Understanding the competitive landscape and sector dynamics is essential for evaluating the long-term prospects of any newly public company in this space. Investors should consider broader market conditions, sector-specific trends, and company fundamentals when assessing GENB as an investment.
Trading History
Generate Biomedicines, Inc. is actively trading in the public markets with a current share price of $12.47. The company went public at $12.45 per share, resulting in gains of 0.2% for IPO investors. With a current market capitalization of $1.6B, Generate Biomedicines, Inc. continues to establish its presence as a publicly traded entity in the Pharmaceutical Preparations.
Important Disclaimer
This analysis of Generate Biomedicines, Inc. (GENB) is provided for informational purposes only and should not be construed as investment advice. All data is sourced from SEC EDGAR filings and public market feeds. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. IPOLockup.io is an independent research platform with no financial interest in any of the companies covered.